Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B

Thrombosis and Haemostasis

Volumn 117, Issue 6, 2017, Pages 1052-1057

  Hua, Baolai ^a   Wu, Runhui ^b   Sun, FeiFei ^c   Luo, Binyu ^c   Alvey, Christine ^c   LaBadie, Robert R ^c   Qu, Peng Roger ^c   Korth Bradley, Joan M ^c   Rendo, Pablo ^c  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PFIZER INC   (United States)

Author keywords

BeneFIX; Chinese; Paediatrics; Pharmacokinetics; Recombinant factor IX

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BETHESDA ASSAY; BLOOD CLOTTING ASSAY; BLOOD SAMPLING; CLINICAL ARTICLE; DIAGNOSTIC PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECOVERY; DRUG TOLERABILITY; HEMOPHILIA B; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MULTICENTER STUDY; PHARMACOKINETIC PARAMETERS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLING TIME; SUBSTITUTION THERAPY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ADOLESCENT; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHILD; CHINA; CLINICAL TRIAL; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SPECIMEN HANDLING; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHILD; CHINA; FACTOR IX; HALF-LIFE; HEMOPHILIA B; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SPECIMEN HANDLING; TIME FACTORS; YOUNG ADULT;

EID: 85020267851     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-10-0765     Document Type: Article

References (15)

1. Roth DA, Kessler CM, Pasi J, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrations. Blood 2001; 98: 3600-3606.
2. Ragni MV, Pasi KJ, White GC, et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-97.
3. Korth-Bradley JM, Rendo P, Smith L, et al. Pharmacokinetics, efficacy, and safety of nonacog alfa in previously treated patients with moderately severe to severe hemophilia B. Clin Ther 2016; 38: 936-944.
4. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233-243.
5. Shapiro AD, Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-525.
6. Monahan PE, Liesner R, Sullivan ST, et al. Safety and efficacy of investigatorprescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-468.
7. Suzuki A, Tomono Y, Korth-Bradley JM. Population pharmacokinetic modeling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B. Haemophilia 2016; 22: e359-366.
8. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-2323.
9. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products, 21 July 2011, EMA/CHMP/BPWP/144552/2009 Committee for medicinal products for human use (CHMP), effective date: February 1, 2012.
10. Chang H-H, Yang Y-L, Hung M-H, et al. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. J Formos Med Assoc 2007; 106: 281-287.
11. Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014; 20:398.
12. Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia 2016; 22: 381-388.
13. Morfini M, Dragani A, Paladino E, et al. Correlation between FIX genotype and pharmacokinetics of nonacog alpha according to a multicentre Italian study. Haemophilia 2016; 22: 537-542.
14. Bjorkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013; 19: 753-757.
15. Feng D, Stafford KA, Broze GJ, Stafford DW. Evidence of clinically significant extravascular stores of factor IX. J Thromb Haemost 2013; 11: 2176-2178.